nsclc
Item
1. histologic or cytologic diagnosis of non-small cell lung cancer.
boolean
C0007131 (UMLS CUI [1])
nsclc ajcc stage, mediastinal lymph nodes
Item
2. presence of biopsy-proven n2 stage iiia, according to the american joint committee on cancer (ajcc), with none of the mediastinal lymph nodes > 3 cm in largest diameter.
boolean
C0007131 (UMLS CUI [1,1])
C1300072 (UMLS CUI [1,2])
C0441915 (UMLS CUI [1,3])
C0449393 (UMLS CUI [1,4])
tumor amenable to surgical resection
Item
3. tumor amenable to surgical resection.
boolean
C0006826 (UMLS CUI [1,1])
C3900053 (UMLS CUI [1,2])
C0728940 (UMLS CUI [1,3])
response evaluation criteria in solid tumors
Item
4. at least one unidimensional measurable lesion meeting response evaluation criteria in solid tumors (recist. 2000).
boolean
C1709926 (UMLS CUI [1])
prior tumor therapy
Item
5. no prior tumor therapy (surgery, radiotherapy, chemotherapy, immunotherapy, or any other type of tumor therapy).
boolean
C0920425 (UMLS CUI [1,1])
C1514463 (UMLS CUI [1,2])
ecog
Item
6. performance status of 0-1 on ecog scale.
boolean
C1520224 (UMLS CUI [1])
age
Item
7. at least 18 years old.
boolean
C0001779 (UMLS CUI [1])
follow-up compliance
Item
8. patient compliance that allows adequate follow-up.
boolean
C3274571 (UMLS CUI [1,1])
C1321605 (UMLS CUI [1,2])
patient condition, radical nsclc surgery
Item
9. medical fitness of patients adequate for radical nsclc surgery.
boolean
C0683521 (UMLS CUI [1,1])
C0007131 (UMLS CUI [1,2])
C0543467 (UMLS CUI [1,3])
C0439807 (UMLS CUI [1,4])
hematologic, hepatic, renal function
Item
10. adequate organ function including the following:adequate hematologic function: wbc count ≥ 4,000/ul, absolute neutrophil count (anc) ≥ 1,500/ul, platelet count ≥ 100,000/ul, and hemoglobin ≥ 10 gm/dl.adequate hepatic function: bilirubin ≤ 1.5 x unl, alt or ast ≤ 2.5 x unl.adequate renal function: creatinine ≤ 1.5mg/dl.
boolean
C0221130 (UMLS CUI [1,1])
C0948762 (UMLS CUI [1,2])
C0005821 (UMLS CUI [1,3])
C0019046 (UMLS CUI [1,4])
C0232741 (UMLS CUI [2,1])
C1278039 (UMLS CUI [2,2])
C0201899 (UMLS CUI [2,3])
C0201836 (UMLS CUI [2,4])
C0232804 (UMLS CUI [3,1])
C0201976 (UMLS CUI [3,2])
informed consent
Item
11. signed informed consent from patient or legal representative.
boolean
C0021430 (UMLS CUI [1])
effective contraception, pregnancy test
Item
12. patients with reproductive potential must use an approved contraceptive method during and for 3 months after the study. females with childbearing potential must have a negative urine hcg test within 7 days prior to study enrollment.
text
C0700589 (UMLS CUI [1])
C0032976 (UMLS CUI [2])
concurrent tumor therapy
Item
1. concurrent administration of any other tumor therapy, including radiotherapy, chemotherapy, immunotherapy.
boolean
C0009429 (UMLS CUI [1,1])
C0920425 (UMLS CUI [1,2])
uncontrolled infection
Item
2. active uncontrolled infection.
boolean
C0009450 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
comorbidities
Item
3. serious concomitant disorders that would compromise the safety of patient or compromise the patient's ability to tolerate therapy.
boolean
C0009488 (UMLS CUI [1])
heart diseases
Item
4. mi within preceding 6 months or symptomatic heart disease including unstable angina, congestive heart failure, or uncontrolled arrhythmia.
boolean
C0018799 (UMLS CUI [1])
neurological or mental disorder
Item
5. significant neurological or mental disorder.
boolean
C0027765 (UMLS CUI [1])
C0004936 (UMLS CUI [2])
second primary malignancy
Item
6. second primary malignancy.
boolean
C0751623 (UMLS CUI [1])
pregnancy, breast feeding
Item
7. pregnant or nursing.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])